Literature DB >> 9973476

Human effector memory T cells express CD86: a functional role in naive T cell priming.

P Jeannin1, N Herbault, Y Delneste, G Magistrelli, S Lecoanet-Henchoz, G Caron, J P Aubry, J Y Bonnefoy.   

Abstract

The glycoprotein CD86 expressed on APCs provides a costimulatory signal necessary for an efficient activation of naive T cells. In contrast, there is controversy about the condition of expression and the function of CD86 on T cells. In this study, we have analyzed the phenotype and the biological activity of CD86+ T cells generated from human PBMC. Results show that CD86 expression on T cells is induced by long term stimulation via CD3 and IL-2R and is down-regulated as the cells become quiescent. The CD86-expressing cells are memory effector T cells: 1) they express CD45RO and high levels of the activation markers CD25, CD54, and HLA-Dr; 2) they selectively express CD30, CD40-ligand, and CD70; and 3) in response to stimulation, most of them produce IFN-gamma before dying by apoptosis. We then analyzed whether CD86 expressed on T cells is functional. Results show that paraformaldehyde-fixed CD86+ T cells enhance the proliferation and production of IFN-gamma by anti-CD3 mAb-stimulated naive T cells and induce proliferation of resting allogenic T cells. All these effects are prevented by neutralizing anti-CD86 mAbs. In contrast, we report no autocrine effect of CD86 in CD86+ T cell activation. In conclusion, these data show that human memory effector T cells express a functional form of CD86 that can costimulate naive T cell responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973476

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Activation antigens on colonic T cells in inflammatory bowel disease: effects of IL-10.

Authors:  E C Ebert; V Mehta; K M Das
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

2.  Novel insights in the regulation of the immune system: a report on the FASEB summer research conference on autoimmunity (June 14-19, 2003, Saxton's River, Vermont, USA).

Authors:  Matthew A Gronski
Journal:  Rev Diabet Stud       Date:  2004-05-10

3.  Epipolymorphisms associated with the clinical outcome of autoimmune arthritis affect CD4+ T cell activation pathways.

Authors:  Roberto Spreafico; Maura Rossetti; John W Whitaker; Wei Wang; Daniel J Lovell; Salvatore Albani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-14       Impact factor: 11.205

4.  Changes in immunological profile as a function of urbanization and lifestyle.

Authors:  Moustapha Mbow; Sanne E de Jong; Lynn Meurs; Souleymane Mboup; Tandakha Ndiaye Dieye; Katja Polman; Maria Yazdanbakhsh
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

5.  Interleukin-15 up-regulates the expression of CD154 on synovial fluid T cells.

Authors:  M Möttönen; P Isomäki; R Luukkainen; P Toivanen; J Punnonen; O Lassila
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

6.  Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound.

Authors:  Michael J Corley; Alina P S Pang; Thomas A Rasmussen; Martin Tolstrup; Ole S Søgaard; Lishomwa C Ndhlovu
Journal:  AIDS       Date:  2021-11-15       Impact factor: 4.177

7.  Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling.

Authors:  Henry Radziewicz; Chris C Ibegbu; Huiming Hon; Nathalie Bédard; Julie Bruneau; Kimberly A Workowski; Stuart J Knechtle; Allan D Kirk; Christian P Larsen; Naglaa H Shoukry; Arash Grakoui
Journal:  J Immunol       Date:  2010-01-25       Impact factor: 5.422

8.  Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle.

Authors:  Jean-François Giguère; Salim Bounou; Jean-Sébastien Paquette; Joaquín Madrenas; Michel J Tremblay
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.

Authors:  Muzaffar H Qazilbash; Neeraj Y Saini; Soung-Chul Cha; Zhe Wang; Edward A Stadtmauer; Veerabhadran Baladandayuthapani; Heather Lin; Beryl Tross; Medhavi Honhar; Sheetal S Rao; Kunhwa Kim; Michael Popescu; Szymon Szymura; Tiantian Zhang; Aaron Anderson; Qaiser Bashir; Elizabeth J Shpall; Robert Z Orlowski; Bruce L Levine; Naseem Kerr; Alfred Garfall; Adam Cohen; Dan T Vogl; Karen Dengel; Carl H June; Richard Champlin; Larry W Kwak
Journal:  Blood       Date:  2022-03-03       Impact factor: 22.113

10.  Molecular profiling of tumor-specific TH1 cells activated in vivo.

Authors:  Kristina Berg Lorvik; Ole Audun Werner Haabeth; Trevor Clancy; Bjarne Bogen; Alexandre Corthay
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.